Phaseline

Targets › PGF

PGF (Placenta growth factor): drug programs, companies and trials

4 programs from 4 companies in 13 trials: 4 Phase 4, 4 Phase 3, 4 Phase 2, 1 Phase 1; Ophthalmology, Metabolic and endocrine, Oncology; next expected readout Jan 2027.

Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. (UniProt, P49763)

Open in Phaseline: the race on PGF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Eye Disease Prevention and Treatment CenterConbercept
Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor
VEGFA, VEGFB, PGF, VEGFCPhase 4Diabetic Macular Edema–
Regeneron PharmaceuticalsAflibercept
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 3Neovascular Age-Related Macular Degeneration; Diabetic Maculopathy; Diabetic Macular Edema (DME); Proliferative Diabetic Retinopathy (PDR) …Jan 2027
Ashvattha TherapeuticsAflibercept (D-4517)
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 2Neovascular Age-related Macular Degeneration–
Samsung BioepisAflibercept (SB15)
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 2Neovascular Age-related Macular Degeneration–

Conditions

Neovascular Age-related Macular Degeneration (3) Diabetic Macular Edema (1) Neovascular Age-Related Macular Degeneration (1) Diabetic Maculopathy (1) Diabetic Macular Edema (DME) (1) Proliferative Diabetic Retinopathy (PDR) (1) Polypoidal Choroidal Vasculopathy (1) Severe Diabetic Macular Oedema (1) Eye Diseases (1) Metastatic Uveal Melanoma (1) Clinical Stage IV Cutaneous Melanoma AJCC v8 (1)

Modalities

antibody (4)

Companies

Shanghai Eye Disease Prevention and Treatment Center (1) Regeneron Pharmaceuticals (1) Ashvattha Therapeutics (1) Samsung Bioepis (1)

Related targets

VEGFA (4) VEGFB (1) VEGFC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.